{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:58:17Z","timestamp":1768967897395,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00228-023-03466-8","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:47:48Z","timestamp":1675997268000},"page":"493-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy"],"prefix":"10.1007","volume":"79","author":[{"given":"K. R.","family":"Doornhof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. D.","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. M.","family":"Boeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E. C. A. B.","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-6619","authenticated-orcid":false,"given":"A.","family":"Daskapan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"3466_CR1","unstructured":"Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey (2018) Available from: https:\/\/clincalc.com\/DrugStats\/Drugs\/Fluorouracil"},{"key":"3466_CR2","unstructured":"Van Halteren HK, Roumen RM, Coebergh JW, Croiset van Uchelen FA, Keuning JJ, Vreugdenhil G (1999) The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer.\u00a0Anticancer Res\u00a019(4C):3447\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10629633"},{"issue":"1","key":"3466_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1524-4733.2002.51083.x","volume":"5","author":"TE Delea","year":"2002","unstructured":"Delea TE et al (2002) The incidence and cost of hospitalization for 5-FU toxicity among medicare beneficiaries with metastatic colorectal cancer. Value in Health 5(1):35\u201343.\u00a0https:\/\/doi.org\/10.1046\/j.1524-4733.2002.51083.x","journal-title":"Value in Health"},{"issue":"10","key":"3466_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin D et al (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32(10):1031\u20131039. https:\/\/doi.org\/10.1200\/JCO.2013.51.1857","journal-title":"J Clin Oncol"},{"key":"3466_CR5","doi-asserted-by":"publisher","unstructured":"Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar H, Henricks LM (2020) Individualized dosing of fluoropyrimidine\u2010based chemotherapy to prevent severe fluoropyrimidine\u2010related toxicity: what are the options?\u00a0Clin Pharmacol Ther\u00a0cpt.2069.\u00a0https:\/\/doi.org\/10.1002\/cpt.2069","DOI":"10.1002\/cpt.2069"},{"key":"3466_CR6","doi-asserted-by":"publisher","unstructured":"Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.\u00a0https:\/\/doi.org\/10.1172\/JCI113308","DOI":"10.1172\/JCI113308"},{"issue":"3","key":"3466_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ et al (2016) Upfront genotyping of DPYD\u22172A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34(3):227\u2013234. https:\/\/doi.org\/10.1200\/JCO.2015.63.1325","journal-title":"J Clin Oncol"},{"key":"3466_CR8","unstructured":"European Medicines Agency, EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine (2020)\u00a0EMA 31(April):3. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine"},{"key":"3466_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","volume":"50","author":"D Meulendijks","year":"2016","unstructured":"Meulendijks D, Cats A, Beijnen JH, Schellens JHM (2016) Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity \u2013 ready for clinical practice? Cancer Treat Rev 50:23\u201334. https:\/\/doi.org\/10.1016\/j.ctrv.2016.08.002","journal-title":"Cancer Treat Rev"},{"key":"3466_CR10","doi-asserted-by":"crossref","unstructured":"van Kuilenburg AB, van Lenthe H, Tromp A, Veltman PC, van Gennip AH (2000) Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem\u00a046(1):9\u201317.\u00a0Available from:\u00a0https:\/\/academic.oup.com\/clinchem\/article\/46\/1\/9\/5670723","DOI":"10.1093\/clinchem\/46.1.9"},{"key":"3466_CR11","unstructured":"Botros M, Sikaris KA (2013) The de ritis ratio: the test of time. Clin Biochem Rev\u00a034(3):17\u201330.\u00a0Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24353357"},{"issue":"3","key":"3466_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt.729","volume":"102","author":"A Levey","year":"2017","unstructured":"Levey A, Inker L (2017) Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther 102(3):405\u2013419. https:\/\/doi.org\/10.1002\/cpt.729","journal-title":"Clin Pharmacol Ther"},{"key":"3466_CR13","unstructured":"Accord Healthcare, SmPC fluorouracil accord 50 mg\/ml, oplossing voor injectie of infusie (2009) Available from:\u00a0https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h100701_smpc.pdf"},{"key":"3466_CR14","unstructured":"Accord Healthcare, SmPC Capecitabine Accord filmomhulde tabletten (2012)\u00a0Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/capecitabine-accord-epar-product-information_nl.pdf"},{"key":"3466_CR15","unstructured":"Millmount Healthcare Limited, SmPC Teysuno 15 mg\/4,35 mg\/11,8 mg harde capsules (2011) Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/teysuno-epar-product-information_nl.pdf"},{"key":"3466_CR16","unstructured":"National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (2017) Available from:\u00a0https:\/\/www.meddra.org\/"},{"issue":"1","key":"3466_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1258\/000456303321016150","volume":"40","author":"ABP van Kuilenburg","year":"2003","unstructured":"van Kuilenburg ABP, De Abreu RA, van Gennip AH (2003) Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem Int J Lab Med 40(1):41\u201345. https:\/\/doi.org\/10.1258\/000456303321016150","journal-title":"Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"},{"key":"3466_CR18","unstructured":"Soong S, Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in Ca relationship between dihydropyrimidine dehydrogenase activity and plasma 5.\u00a0Available from: https:\/\/www.researchgate.net\/publication\/20861639"},{"issue":"5","key":"3466_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4155\/bio.14.304","volume":"7","author":"D Pluim","year":"2015","unstructured":"Pluim D et al (2015) Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis 7(5):519\u2013529. https:\/\/doi.org\/10.4155\/bio.14.304","journal-title":"Bioanalysis"},{"issue":"2","key":"3466_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"issue":"3\u20134","key":"3466_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","volume":"79","author":"G Milano","year":"1999","unstructured":"Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Ren\u00e9e N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79(3\u20134):627\u2013630. https:\/\/doi.org\/10.1038\/sj.bjc.6690098","journal-title":"Br J Cancer"},{"key":"3466_CR22","unstructured":"van Kuilenburg AB\u00a0et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res6(12):4705\u201312. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11156223"},{"issue":"3","key":"3466_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","volume":"49","author":"C Poole","year":"2002","unstructured":"Poole C et al (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49(3):225\u2013234. https:\/\/doi.org\/10.1007\/s00280-001-0408-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3466_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/pharmaceutics11050199","volume":"11","author":"TJ Wigle","year":"2019","unstructured":"Wigle TJ, Tsvetkova EV, Welch SA, Kim RB (2019) DPYD and fluorouracil-based chemotherapy: mini review and case report. Pharmaceutics 11(5):199. https:\/\/doi.org\/10.3390\/pharmaceutics11050199","journal-title":"Pharmaceutics"},{"issue":"2","key":"3466_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.taap.2004.08.018","volume":"203","author":"F Innocenti","year":"2005","unstructured":"Innocenti F, Danesi R, Bocci G, Natale G, Del Tacca M (2005) 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. Toxicol Appl Pharmacol 203(2):106\u2013113. https:\/\/doi.org\/10.1016\/j.taap.2004.08.018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"3466_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.20878","volume":"103","author":"K Chansky","year":"2005","unstructured":"Chansky K, Benedetti J, Macdonald JS (2005) Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103(6):1165\u20131171. https:\/\/doi.org\/10.1002\/cncr.20878","journal-title":"Cancer"},{"issue":"8","key":"3466_CR27","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III study. J Clin Oncol 19(8):2282\u20132292. https:\/\/doi.org\/10.1200\/JCO.2001.19.8.2282","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03466-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03466-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T09:04:34Z","timestamp":1679648674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03466-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3466"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03466-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from the data obtained for clinical purposes. We consulted extensively with the local scientific committee of Tergooi Medical Center which determined that our study did not need ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was deemed unnecessary due to anonymized data and due to the observational nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was deemed unnecessary due to anonymized data and due to the observational nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}